Related Experiment Video
Updated: Aug 16, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Nucleoside/nucleotide backbones for the treatment of HIV infection
Pablo Barreiro1, Inmaculada Jiménez-Nácher, Benito García
1Service of Infectious Diseases and Service of Pharmacy, Hospital Carlos III, Madrid 28029, Spain.
Abstract:
Nucleoside/nucleotide analogs (NAs) are essential components of most current antiretroviral regimens. Although many dual NA combinations may be used as backbones, not all display optimal results. For instance, some associations should be avoided due to antagonism (eg, zidovudine plus stavudine), high rates of toxicity (eg, didanosine plus stavudine) and/or increased risk of virological failure (eg, didanosine plus tenofovir). Moreover, the knowledge of plasma and intracellular interactions between different NAs is important for choosing appropriate combinations and optimal doses in order to optimize antiviral efficacy and minimize toxicities.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
DNA Base Pairing
Inhibitors of Viral Protein Synthesis
Retroviruses

